Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-01
2008-01-01
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S295000
Reexamination Certificate
active
10511438
ABSTRACT:
The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation.
REFERENCES:
patent: 2005/0261304 (2005-11-01), Gaillard et al.
patent: 11-080155 (1999-03-01), None
patent: 01/47920 (2001-07-01), None
patent: 02/26711 (2002-04-01), None
Sah et al., Translation Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) by Activating c-Jun N-terminal Kinase, The Journal of Biological Chemistry, vol. 278, No. 23, pp. 20593-26002, Jun. 2003.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Roger J. Davis, “Signal transduction by the JNK group of MAP kinases”, CELL, vol. 103, pp. 239-252 Oct. 13, 2000.
Shashi Gupta, et al., “Selective interaction of JNK protein kinase isoforms with transcription factors”, The EMBO Journal, vol. 15, No. 11, pp. 2760-2770 1996.
Calin D. Dumitru, et al., “TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway”, CELL, vol. 103, pp. 1071-1083 Dec. 22, 2000.
Zuoning Han, et al., “c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis”, The Journal of Clinical Investigation, vol. 108, No. 1, pp. 73-81, 2001.
Hiroshi Nishina, et al., “Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4(MKK4)-deficient T lymphocytes”, The Journal of Experimental Medicine, vol. 186, No. 6, pp. 941-953 Sep. 15, 1997.
Stephan J. Kempiak, et al., “the jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the IκBkinase cascade”, The Journal of Immunology, vol. 162, pp. 3176-3187 1999.
S. M. de la Monte, et al., “Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells”, Journal of Alzheimer's Disease, vol. 2, pp. 261-281 2000.
Xiongwei Zhu, et al., “Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease”, Journal of Neurochemistry, vol. 76, pp. 435-441 2001.
Li Xu, et al., “Assess the in vivo activation of signal transduction pathways with pathdetect reporting systems”, STRATEGIES, vol. 11, pp. 94-97 2001.
Mausumee Guha, et al., “LPS induction of gene expression in human monocytes”, Cellular Signalling, vol. 13, pp. 85-94 2001.
A. Jackie Hunter, et al., “Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs”, TIPS, vol. 16, pp. 123-128 1995.
F. Block, “Global ischemia and behavioural deficits”, Progress in Neurobiology, vol. 58, pp. 279-295 1999.
Susan C. Gerhardt, et al., “Motor activity changes following cerebral ischemia in gerbils are correlated with the degree of neuronal degeneration in hippocampus”, Behavioral Neuroscience, vol. 102, No. 2, pp. 301-303 1988.
A. Lorris Betz, et al., “Blood-brain-cerebrospinal fluid barriers”, Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, 5thedition, chapter 32, pp. 681-699, 1994.
Gary W. Goldstein, et al., “The blood-brain barrier”, Scientific American, pp. 70-79 Sep. 1986.
U.S. Appl. No. 10/571,291, filed Mar. 9, 2006, Gaillard, et al.
Gaillard Pascale
Gotteland Jean-Pierre
Vitte Pierre-Alain
Laboratories Serono SA
Rao Deepak
LandOfFree
Piperazine benzothiazoles as agents for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine benzothiazoles as agents for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine benzothiazoles as agents for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3958333